Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity
- 7 February 2019
- journal article
- research article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 96 (5), 368-374
- https://doi.org/10.1002/cyto.b.21770
Abstract
Background High‐grade B‐cell lymphomas (HGBCL) with MYC and BCL2 or/and BCL6 rearrangements (R), so‐called double/triple‐hit lymphomas (DH/THL), are uncommon, clinically aggressive lymphomas that require a prompt diagnosis. We aim to identify flow cytometric immunophenotypic (IP) features of DH/THL that may aid in triaging these cases followed by a timely confirmatory cytogenetic study. Methods We compared the IP features of 43 cases of DH/THL to those of 55 cases of single‐hit lymphoma (SHL) and 59 cases of diffuse large B‐cell lymphoma (DLBCL) without MYC‐R (MYCneg DLBCL). We analyzed the expression patterns of CD10, CD19, CD20, CD38, and surface immunoglobulin light chain in lymphoma cells. Results Bright CD38 expression (CD38bright) analyzed either qualitatively or semi‐quantitatively was more common in DH/THL (56%) than in MYCneg DLBCL (17%) but less common compared to SHL (82%), indicating that CD38bright can serve as a biomarker for DH/THL. Additionally, CD38bright may be a better indicator for predicting DH/THL‐BCL2 than DHL‐BCL6, and very bright CD38 expression was exclusive to MYC rearranged lymphomas. The expression patterns of other markers were similar among these lymphoma groups. Conclusions CD38bright is a biomarker associated with DH/THL with a moderate sensitivity (~50%) and high specificity (~90%). While this marker cannot be used as a screening tool, awareness of this correlation may aid in expediting the diagnosis and prioritizing FISH testing in resource limited settings or situations when samples are limited. Future studies to combine immunohistochemical markers are needed to further enhance the predictive power of CD38bright in diagnosing DH/THL. © 2019 International Clinical Cytometry SocietyKeywords
This publication has 16 references indexed in Scilit:
- Double-hit DLBCL: should we limit FISH testing?Blood, 2018
- Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangementsBlood, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHCHematology, 2014
- Double-hit lymphomas: current paradigms and novel treatment approachesHematology, 2014
- Flow cytometry is of limited utility in the early identification of “Double-hit” B-cell lymphomasCytometry Part B: Clinical Cytometry, 2013
- The Unique Immunophenotype of Double-Hit LymphomasAmerican Journal of Clinical Pathology, 2011
- “Double-Hit” Mature B-Cell Lymphomas Show a Common Immunophenotype by Flow Cytometry That Includes Decreased CD20 ExpressionAmerican Journal of Clinical Pathology, 2010
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survivalBlood, 2009
- Bright CD38 expression is an indicator ofMYCrearrangementLeukemia & Lymphoma, 2009